Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioRestorative Therapies, Inc. (BRTX)

BioRestorative Therapies R&D VP resigns; $1.29 million severance claim not accepted

Negative Impact 3 of 5 leadership Written later

BioRestorative Therapies received a notice on September 4, 2026 from Mr. Silva resigning as Vice President of Research and Development and from any other officer positions, effective immediately. The notice claims Good Reason and a Change in Control, and Mr. Silva has demanded severance, which the board has not accepted. The dispute and an ongoing board-directed investigation into the related employment agreements could create legal and financial uncertainty for shareholders.

Key points

  • Resignation notice received September 4, 2026; effective immediately
  • Mr. Silva claims cash severance of approximately $1.29 million, plus equity acceleration and benefits, if the Good Reason claim is upheld
  • Board acknowledged the resignation for records purposes but does not accept the Employment Agreement or the Good Reason and Change in Control claims, and has reserved all rights
  • Pending investigation, no payments under the agreement other than accrued salary and legally required amounts

The filing

CompanyBioRestorative Therapies, Inc. (BRTX)
Form8-K, current report
Filed with the SECSep 11, 2026, 9:29 AM ET
Accession number0001213900-26-099018

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.